Enveric Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Enveric Biosciences

28/03/2025 23:01

Enveric Biosciences Inc ENVB.OQ reported a quarterly adjusted loss of $4.80​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-22.05.  The lone analyst forecast for the quarter was for a loss of 23 cents per share.

Reported revenue was zero​; analysts expected zero.

Enveric Biosciences Inc's reported EPS for the quarter was a loss of $4.80​.

The company reported a quarterly loss of $3.16 million.

Enveric Biosciences Inc shares had fallen by 70.2% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 96.2% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Enveric Biosciences Inc is $54.80

This summary was machine generated from LSEG data March 28 at 11:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.23
-4.80
Missed
Sep. 30 2024
-7.80
-3.60
Beat
Jun. 30 2024
-8.25
-3.75
Beat
Mar. 31 2024
-11.62
-9.15
Beat